MetaCap

BGM Group (BGM) vs Genelux (GNLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Genelux (GNLX) has outperformed BGM Group (BGM) over the past year, losing 56.3% versus a loss of 96.7%. BGM Group is the larger company by market cap ($108.6 million vs $103.4 million), about 1.1 times the size. BGM Group converts more of its revenue into profit, with a net margin of -52.6% versus -401812.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BGM-96.73%GNLX-54.03%
+18%-42%-103%
Nov 21, 20251 yearNov 19, 2026
BGM-95.99%GNLX-63.89%
+511%+193%-125%
Jan 23, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BGM versus GNLX key metrics
MetricBGMGNLX
Share price$8.13$2.17
Market cap$108.57M$103.36M
1-day change0.00%-4.82%
YTD return-92.77%-50.23%
1-year return-96.73%-56.25%
5-year return-98.31%—
EPS (TTM)$-4.80$-0.88
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$37.92M$8.00K
Revenue growth (YoY)+51.09%0.00%
Net income (latest FY)$-19.94M$-32.15M
Gross margin16.64%—
Operating margin-33.18%-415175.00%
Net margin-52.59%-401812.50%
52-week high$263.70$5.89
52-week low$0.00$1.77
Distance from 52-week high-96.92%-63.16%
Analyst consensus—strong_buy
Avg. price target upside—+767.74%
Average volume6.18K333.31K
Shares outstanding12.69M47.63M
Employees—25
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GNLX has outperformed BGM by 40.5 percentage points over the past year.
  • BGM Group is more profitable, keeping -52.6 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
  • BGM Group grew revenue faster in its latest fiscal year (+51.09% vs 0.00%).

About BGM Group

BGM stock →

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.

Health Care · Biotechnology: Pharmaceutical Preparations

About Genelux

GNLX stock →

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

BGM vs GNLX FAQ

Which is bigger, BGM Group or Genelux?

BGM Group (BGM) is larger, with a market capitalization of $108.57M compared with $103.36M for Genelux (GNLX).

Which stock has performed better over the past year, BGM or GNLX?

GNLX returned -56.25% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.

Are BGM Group and Genelux in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons